Overview
- A pre-specified interim Phase 3 analysis found that the individualized mRNA vaccine given with pembrolizumab significantly improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab alone in completely resected stage IIB–IV melanoma and showed no new safety signals.
- Moderna and Merck say the trial will continue to follow patients to evaluate overall survival and other endpoints while they prepare to present full, detailed efficacy and safety data to the scientific community and regulators.
- The therapy is bespoke: a patient’s tumor is sequenced, up to 34 neoantigen targets are chosen by algorithm, and a tailored mRNA dose is manufactured over several weeks, a process that raises major scale and cost challenges for broad use.
- Investors drove a dramatic surge in Moderna’s share price and hedge funds increased positions, but analysts caution market gains outpaced likely commercial outcomes because melanoma’s high mutation burden and immunotherapy sensitivity may not apply to other cancers.
- This result is the first late-stage positive readout for an individualized neoantigen mRNA therapy and it strengthens the platform’s proof of concept while leaving open key questions on long-term benefit, subgroup effects, pricing, reimbursement, and manufacturing capacity.